Chronic cardiopulmonary diseases including pulmonary hypertension (PH), pulmonary thrombosis and embolism (PTE), pulmonary fibrosis (PF), cardiac hypertrophy and heart failure etc. are progressive and fatal diseases that seriously affect the quality of life, are recognized as heavy challenges to public health management. Due to the high rates of mortality and disability, patients with chronic cardiopulmonary diseases are usually subjected to considerable economic and psychosocial burdens.
Chronic cardiopulmonary diseases are mostly caused by genetic and environmental factors and/or social behaviors. Clinical therapy for cardiopulmonary diseases made great progress during the past decades but remains a serious problem. For example, pulmonary hypertension is a destructive disease of the pulmonary vasculature leading to right heart failure and eventually death and is also known as "cardiovascular cancer". Despite progress in understanding the pathological mechanisms of these diseases, current therapeutic intervention strategies only slow disease progression. There are still no clinically effective therapies available to halt disease progression or reverse the morphological and functional injury. In recent years, many studies have investigated pathological mechanisms underlying these cardiopulmonary diseases to identify novel early biomarkers and specific signaling pathways that could be targeted for the development of novel effective drug treatment.
This Research Topic aims to address the biochemistry and molecular genetics of cardiopulmonary diseases processes. Basic and clinical research articles should emphasize the underlying mechanisms of disease pathways and provide significant contributions to the understanding and/or treatment of cardiopulmonary diseases including pulmonary hypertension (PH), pulmonary thrombosis and embolism (PTE), pulmonary fibrosis (PF), cardiac hypertrophy and heart failure, among others. Furthermore, this Research Topic also invites authors to submit articles focused on drug combinations and adverse drug reactions. In addition, we are also interested in research related to investigational new drug (IND) and clinical trials for chronic cardiopulmonary diseases.
Chronic cardiopulmonary diseases including pulmonary hypertension (PH), pulmonary thrombosis and embolism (PTE), pulmonary fibrosis (PF), cardiac hypertrophy and heart failure etc. are progressive and fatal diseases that seriously affect the quality of life, are recognized as heavy challenges to public health management. Due to the high rates of mortality and disability, patients with chronic cardiopulmonary diseases are usually subjected to considerable economic and psychosocial burdens.
Chronic cardiopulmonary diseases are mostly caused by genetic and environmental factors and/or social behaviors. Clinical therapy for cardiopulmonary diseases made great progress during the past decades but remains a serious problem. For example, pulmonary hypertension is a destructive disease of the pulmonary vasculature leading to right heart failure and eventually death and is also known as "cardiovascular cancer". Despite progress in understanding the pathological mechanisms of these diseases, current therapeutic intervention strategies only slow disease progression. There are still no clinically effective therapies available to halt disease progression or reverse the morphological and functional injury. In recent years, many studies have investigated pathological mechanisms underlying these cardiopulmonary diseases to identify novel early biomarkers and specific signaling pathways that could be targeted for the development of novel effective drug treatment.
This Research Topic aims to address the biochemistry and molecular genetics of cardiopulmonary diseases processes. Basic and clinical research articles should emphasize the underlying mechanisms of disease pathways and provide significant contributions to the understanding and/or treatment of cardiopulmonary diseases including pulmonary hypertension (PH), pulmonary thrombosis and embolism (PTE), pulmonary fibrosis (PF), cardiac hypertrophy and heart failure, among others. Furthermore, this Research Topic also invites authors to submit articles focused on drug combinations and adverse drug reactions. In addition, we are also interested in research related to investigational new drug (IND) and clinical trials for chronic cardiopulmonary diseases.